(Reuters) – Sanofi said on Thursday that it would acquire Vigil Neuroscience, a clinical-stage biotech company, for $8 per share in cash, valuing the deal at about $470 million.
(This story has been refiled to change the dateline to May 22)
(Reporting by Bipasha Dey in Bengaluru; Editing by Mohammed Safi Shamsi)
